Skip to main content

Nervous System Diseases

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
FerumoxytolPhase 21 trial
Active Trials
NCT00659776Terminated255Est. Dec 2021
Takeda
TakedaTOKYO, Japan
1 program
SHP615PHASE_32 trials
Active Trials
NCT03336450Completed3Est. Oct 2020
NCT03336645Completed25Est. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaSHP615
TakedaSHP615
Oregon TherapeuticsFerumoxytol

Clinical Trials (3)

Total enrollment: 283 patients across 3 trials

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

Start: Apr 2018Est. completion: Oct 20203 patients
Phase 3Completed

Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan

Start: Oct 2017Est. completion: Aug 201925 patients
Phase 3Completed

MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation

Start: Jul 2004Est. completion: Dec 2021255 patients
Phase 2Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.